



AForm PTO-1449

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.  
**R103 1030.1**Serial No.  
**10/059,521**Applicant  
**Rich, Ivan**Filing Date  
**January 29, 2002**

Group

## U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A						
	B						
	C						
	D						
	E						
	F						
	G						

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	H							
	I							
	J							
	K							
	L							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

gib	M	"Circannual Variations Of Circadian Periodicity In Murine Colony-Forming Cells"; Aardal, Nils-Petter, Experimental Hematology, 12:61-67 (1984)
gib	N	"Circadian Variations in Mouse Bone Marrow"; Aardal, N.P. & Laerum, O.D., Experimental Hematology, Vol. 11, No. 9, pp. 792-801 (1983)
gib	O	"Cyclic Hematopoiesis in Dogs: Studies of Erythroid Burst-forming Cells Confirm an Early Stem Cell Defect"; Abkowitz, Janis L., Holly, Richard D., Hammond, William P. IV, Experimental Hematology, 16:941-945 (1988)

Doris R. Babel  
2/1/05

RECEIVED

FEB 12 2003  
Sheet 2 of 5

888	P 4	"Hematopoietic Effects of Benzene Inhalation Assessed by Long-term Bone Marrow Transplantation"; Abraham, Nadar G., Environmental Health Perspectives, Vol. 104, Supplement 6, pp. 1277-82 (1996)
888	Q 5	"Circadian cell cycle variations of erythro- and myelopoiesis in humans"; Abrahamsen, JF, Smaaland, R, Sothorn, RB, Laerum OD, European Journal of Haematology, Vol. 58, pp. 333-45 (1997)
888	R 6	"Circadian and seasonal variations of hematopoiesis in cord blood"; Baudoux, E., et al, Bone Marrow Transplantation, Supplement 1, S12, p. 22 (1998)
888	S 7	"Toxicity on Human Hemopoietic Progenitors of 2'-2'-Difluoro-2'Deoxyctidine (Gemcitabine)"; Botta, Marco, et al, Anticancer Research, Vol. 18, pp. 1037-42 (1998)
888	T 8	"Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis"; Bradbury, D.A., Simmons, T.D., Slater, K.J., Crouch, S.P.M., Journal of Immunological Methods 240, pp. 79-92 (2000)
888	U 9	"The Growth Of Mouse Bone Marrow Cells <i>In Vitro</i> "; Bradley, T.R., Metcalf, D, Aust. J. Experimental Biological Medical Science, 44, pp. 287-300 (1966)
888	V 10	"Cyclic oscillations of neutrophils, monocytes, and CD8-positive lymphocytes in a healthy subject"; Carulli, Giovanni, et al, Haematologica, Vol. 85(4), pp. 447-48 (2000)
888	W 11	"Azidothymidine and interferon- $\alpha$ in vitro effects on hemotopoiesis: Protective in vitro activity of IL-1 and GM-CSF"; Castello, G, et al, Experimental Hematology 23, pp. 1367-71 (1995)
888	X 12	"Hematotoxicity of 5-Fluorouracil-Leucovorin in a Setting of Adjuvant Chemotherapy"; Cerruti, Alessandro, et al, Anticancer Research 14, pp. 2163-66 (1994) → (65) ?
888	Y 13	"Chemopreventive Agent Resveratrol, a Natural Product Derived From Grapes, Triggers CD95 Signaling-Dependent Apoptosis in Human Tumor Cells"; Clement, M., et al, Blood, Vol. 92, No. 3, pp. 996-1002 (1998)
888	Z 14	"Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin"; Corsini, C., et al, British Journal of Cancer, 82(3), pp. 524-528 (2000)
888	AA 15	"The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity"; Crouch, S.P.M., et al, Journal of Immunological Methods, 160, pp. 81-88 (1993)
888	BB 16	"Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds"; Dox, F., et al, Cancer Chemother Pharmacol, 28, pp. 308-310 (1991)
888	CC 17	"Benzene-Induced Hematotoxicity and Bone Marrow Compensation in B6C371 Mice"; Farris, Georgia M., et al, Fundamental and Applied Toxicology 36, pp. 119-29 (1997)
888	DD 18	"Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites"; Ghielmini, M., et al, Cancer Chemother Pharmacol 42, pp. 235-40 (1998)
888	EE 19	" <i>In vitro</i> schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743)"; Ghielmini, M., et al, Annals of Oncology 9, pp. 989-93 (1998)

Sailore R. Doherty  
2/1/05

FEB 12 2003

Sheet 3 of 5

TECH CENTER 1600/2900

88/20	FF	"Differential toxicity of anticancer drugs on late (GM-CFC) and early (LTC-IC) hemopoietic progenitors <i>in vitro</i> "; Ghielmini, M., et al, Cell Biology and Toxicology 15, pp. 395-404 (1999)
88/21	GG	"Inhibition of CFU-E/BFU-E by 3'-Azido-3'-doxythymidine, Chlorpropamide, and Protoporphirin IX Zinc (II): A Comparison between Direct Exposure of Progenitor Cells and Long-Term Exposure of Bone Marrow Cultures"; Gribaldo, L., et al, Toxicological Sciences 58, pp. 96-101 (2000)
88/22	HH	"Hemotopoietic dynamics in grey collies"; Haurie, Caroline, et al, Experimental Hematology 27, pp. 1139-48 (1999)
88/23	II	"The Organization of Hemopoietic Tissue as Inferred from the Effects of 5-Fluorouracil"; Hodgson, G.S., Bradley, T.R. & Radley, J.M., Experimental Hematology, Vol. 10, No. 1, pp. 26-35 (1982)
88/24	JJ	"In Vitro Production of CFU-S and Cells with Erythropoiesis Repopulating Ability by 5-Fluorouracil Treated Mouse Bone Marrow"; Hodgson, G.S., Bradley, T.R. & Radley, J.M., International Journal of Cell Cloning 1, pp. 49-56 (1983)
88/25	KK	"Monoterpenes As Regulators Of Malignant Cell Proliferation"; Hohl, Raymond J., Adv. Exp. Med. Biol., Vol. 401, pp. 136-146 (1996)
88/26	LL	"The Myelotoxicity of chloramphenicol: <i>in vitro</i> and <i>in vivo</i> studies: I. <i>In vitro</i> effects on cells in culture"; Holt, D.E., et al, Hum. Exp. Toxicol., Vol. 16, pp. 570-576 (1997)
88/27	MM	"Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar"; Horowitz, D. & King, Andrew G., Journal of Immunological Methods 244, pp. 49-58 (2000)
88/28	NN	"Erythroid Colony Formation in Cultures of Mouse and Human Bone Marrow: Analysis of the Requirement for Erythropoietin by Gel Filtration and Affinity Chromatography on Agarose-Concanavalin A"; Iscove, N., Sieber, F. & Winterhalter, H., Journal of Cell. Physiology, 83, pp. 309-320 (1974)
88/29	OO	"A Miniaturized Agar Culture System for Cloning Human Erythropoietic Progenitor Cells"; Konwalinka, G., et al, Experimental Hematology, Vol. 12, pp. 75-79 (1984)
88/30	PP	"Use of the Microculture Kinetic Assay of Apoptosis to Determine Chemosensitivities of Leukemias"; Kravtsov, V.D., et al, Blood, Vol. 92, No. 3, pp. 968-980 (1998)
88/31	QQ	"Chrono Biological Aspects Of Bone Marrow And Blood Cells"; Laerum, O.D. & Aardal, N.P., 11 <sup>th</sup> Int'l Congress of Anatomy: Biological Rhythms in Structure and Function, pp. 87-97 (1981)
88/32	RR (32)	"Hematopoiesis occurs in rhythms"; Laerum, O.D., Experimental Hematology 23, pp. 1145-47 (1995)
88/33	SS	" <i>In Vitro</i> Toxicity of A 3'-Azido-3'-Deoxythymidine and Hydroxyurea Combination on Normal Myeloid Progenitors"; Lerza, R., et al, Anticancer Research 18, pp. 2755-58 (1998)
88/34	TT	"Improved Plasma Culture System for Production of Erythrocytic Colonies In Vitro: Quantitative Assay Method for CFU-E"; McLeod, D.L., et al, Blood, Vol. 44, No. 4, pp. 517-534 (1974)
88/35	UU	"Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays"; Mosman, Tim, Journal of Immunological Methods, Vol 65, pp. 55-63 (1983)

Barbara R. Gohl  
2/10/05

FEB 12 2003

TECH CENTER 1600/2950

88/	VV 36	"A sensitive sandwich ELISA for measuring erythropoietin in human serum"; Noe, G., et al, British Journal of Haematology, Vol. 80, pp. 285-292 (1992)
88/	WW 37	"Roles for In Vitro Myelotoxicity Tests in Preclinical Drug Development and Clinical Trial Planning"; Parchment, R.E., et al, Toxicologic Pathology, Vol. 21, No. 2, pp. 241-50 (1993)
88/	XX 38	"Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from <i>in vitro</i> tests"; Parchment, R.E., et al, Ann Oncol., Vol. 9, pp. 357-364 (1998)
88/	YY 39	"In vitro Study of Pesticide Hematotoxicity in Human and Rat Progenitors"; Parent-Massin, D. & Thouvenot, D., Journal of Pharmacological and Toxicological Methods, Vol. 30, pp. 203-207 (1993)
88/	ZZ 40	"Use of Limiting-Dilution Type Long-Term Marrow Cultures in Frequency Analysis of Marrow-Repopulating and Spleen Colony-forming Hematopoietic Stem Cells in the Mouse"; Ploemacher, R.E., et al, Blood, Vol. 78, No. 10, pp. 2527-2533 (1991)
88/	AAA 41	"The Induction of Clones of Normal Mast Cells By A Substance From Conditioned Medium"; Pluznik, D.H. & Sachs, L., Experimental Cell Research, Vol. 43, pp. 553-63 (1966)
88/	BBB 42	"The Effect of Stem Cell Proliferation Regulators Demonstrated With an <i>in vitro</i> Assay"; Pragnell, I.B., et al, Blood, Vol. 72, No. 1, pp. 196-201 (1988)
88/	CCC 43	"ECVAM's in-house prevalidation/validation studies in the areas of haematotoxicity, reproductive toxicity, metabolism-mediated toxicity and epithelial barrier function"; Prieto, Pilar, The Sciences of the Total Environment, Vol. 247, pp. 349-354 (2000)
88/	DDD 44	"The Effect of 5-Fluorouracil on Erythropoiesis"; Rich, Ivan, Blood, Vol. 77, No. 6, pp. 1164-70 (1991)
88/	EEE 45	"The Developmental Biology of Hemopoiesis: Effect of Growth Factors on the Colony Formation by Embryonic Cells"; Rich, Ivan, Experimental Hematology, Vol. 20, pp. 368-70 (1992)
88/	FFF 46	"Specific Enhancement of Mouse CFU-E by Mouse Transferrin"; Rich, Ivan, et al, British Journal of Haematology, Vol. 49, pp. 567-573 (1981)
88/	GGG 47	"The effect of reduced oxygen tension on colony formation of erythropoietic cells <i>in vitro</i> "; Rich, Ivan, & Kubanek, B., British Journal of Haematology, Vol. 52, pp. 579-588 (1982)
88/	HHH 48	"Haemopoietic stem cells are organized for use on the basis of their generation-age"; Rosendaal, M., et al, Nature, Vol. 264, pp. 68-69 (1976)
88/	III 49	"Circadian Variation in Cell Division of the Mouse Alimentary Tract, Bone Marrow and Corneal Epithelium"; Scheving, L., et al, Anat. Rec., Vol. 191, pp. 479-486 (1978)
88/	JJJ 50	"The Toxicology of Benzene"; Synder, Robert., et al, Environmental Health Perspectives, Vol. 100, pp. 293-306 (1993)
88/	KKK 51	"What controls hair follicle cycling?"; Stenn, K.S., et al, Experimental Dermatology, Vol. 8, pp. 229-236 (1999) 236
88/	LLL 52	"Distinct circadian time structures characterize myeloid and erythroid progenitor and multipotential cell clonogenicity as well as marrow precursor proliferation dynamics"; Wood, Patricia, et al, Experimental Hematology, Vol 26, pp. 523-533 (1998)

Joeline B. Stahl  
2/1/05

RECEIVED

FEB 12 2003

Sheet 5 of 5  
TECH CENTER 1600/2900

88	MMM 53	"Expression of the Circadian Clock Genes <i>clock</i> and <i>period1</i> in Human Skin"; Zanello, Susana, et al, Journal of Invest Dermatol., Vol. 115, pp. 757-760 (2000)
88	NNN 54	"The sensitivity of in vitro erythropoietic progenitor cells to different erythropoietin reagents during development and the role of cell death in culture"; Zimmerman, Frank & Rich, Ivan, Experimental Hematology, Vol. 24, pp. 330-39 (1996)

Guilene B. Babel  
2/1/05

APR 07 2003  
Form PTG-14

Sheet 1 of 1

Form ETD-1449

Attorney Docket No.  
R103 1030.1

**Serial No.**  
**10/059,521**

### INFORMATION DISCLOSURE CITATION

*(Use several sheets if necessary)*

**Applicant**

**RICH, Ivan**

**Filing Date**  
**01/29/2002**

Group

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


AVAILABLE COPY

\* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE:

DATE CONSIDERED:

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE